19:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
02:17 , Jun 9, 2018 |  BioCentury  |  Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago. Deciphera...
18:09 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture studies suggest inhibiting KIF15 alone or in combination with KSP could help treat cancer. In HeLa cells, a tool compound KIF15 inhibitor decreased proliferation compared with no treatment, and the KIF15 inhibitor...
21:51 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

4SC reports Phase I data for resminostat in pancreatic and biliary tract cancer

In September, 4SC AG (Xetra:VSC) said partner Yakult Honsha Co. Ltd. (Tokyo:2267) reported data from a Phase I trial in 27 patients with advanced pancreatic or biliary tract cancer showing that resminostat (4SC-201) plus Teysuno...
20:22 , Jul 28, 2017 |  BC Week In Review  |  Company News

4SC grants Maruho rights to KCNA3-targeted compounds

4SC AG (Xetra:VSC) granted Maruho Co. Ltd. (Osaka, Japan) exclusive, worldwide rights to a class of preclinical compounds targeting potassium channel Kv1.3 (KCNA3). 4SC will be eligible for up to €103 million ($119.9 million) in...
20:32 , Jul 21, 2017 |  BC Week In Review  |  Financial News

4SC closes €40.9M follow-on

On July 6, 4SC AG (Xetra:VSC) raised €40.9 million ($46.8 million) through the sale of 11.7 million shares at €3.50 in a follow-on underwritten by Stifel and quirin bank. The company said it will use the...
22:30 , Apr 14, 2017 |  BioCentury  |  Emerging Company Profile

Tolerating DHODH

Immunic AG is betting on the tolerability and efficacy of its oral, next-generation dihydroorotate dehydrogenase inhibitor to differentiate it from first-generation agents and give it an edge over other types of oral therapies in the...
07:00 , Oct 31, 2016 |  BC Extra  |  Company News

Management tracks

Rainer Boehm is retiring as chief commercial and medical affairs officer at the Novartis Pharma AG division of Novartis AG (NYSE:NVS; SIX:NOVN). Dhaval Patel is also retiring as European head of Novartis Institutes for BioMedical...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Mouse studies suggest inhibiting DHODH could help treat acute AML. In two mouse models of AML, a DHODH inhibitor tool compound increased survival and the levels of markers of differentiation and...
07:00 , Oct 17, 2016 |  BioCentury  |  Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...